ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

NCT05609994 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Low Grade Glioma of Brain

Interventions

DRUG: PEPIDH1M vaccine + vorasidenib

Sponsor

Katy Peters, MD, PhD

Collaborators

[object Object]